-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Next-Generation Therapy for Lower Risk MDS

Program: Education Program
Session: Are We Personalizing MDS Therapy in 2023?
Hematology Disease Topics & Pathways:
drug development, Diseases, Therapies, Myeloid Malignancies
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Marie Sebert, MD, PhD

Hôpital Saint-Louis, Paris, France

Disclosures: Sebert: Abbvie: Honoraria; Servier: Honoraria, Research Funding; Jazz pharmaceuticals: Honoraria; Gilead: Honoraria; Novartis: Honoraria; BMS: Honoraria.

OffLabel Disclosure: